



DD*in*

DRUG DISCOVERY INSIGHTS

LAB282

Joint effort to select
and accelerate early-stage
projects out of Oxford University





LAB282

Accelerating Oxford Drug Discovery

To learn more, please visit: www.lab282.org

Mission


- ▶ Optimise and accelerate drug discovery programmes across any therapeutic area and for any therapeutic modality originated by Oxford University researchers
- ▶ Development of new treatments and cures for serious and debilitating diseases
- ▶ Translating academic science into highest quality drug discovery projects
- ▶ Spin-out companies from the university could be formed to further develop new therapies, supported by the LAB282 partners and/or new investors

Background

- ▶ Partners create a new blueprint for academic translation – Evotec, Oxford Sciences Innovation, Oxford University Innovation and the University of Oxford
- ▶ Utilising the joint strengths of academia, biotechnology and strong links to Pharma

LAB282 agreement

- ▶ Fund size of £ 13 m (> € 14 m)
- ▶ Initial term of 3 years
- ▶ New projects will be sourced exclusively from Oxford University researchers and Evotec across any therapeutic area and for any therapeutic modality
- ▶ Funding will come from OSI
- ▶ New projects will be scouted by an expert in residence from Evotec
- ▶ Evotec will provide “at cost” its full range of drug discovery services in addition to other resources.
- ▶ Evotec will participate in company formation via equity and future R&D upside




DID YOU KNOW?

FACTS ABOUT BUSINESS INCUBATORS



THE NUMBER OF BUSINESS INCUBATORS ROSE FROM NEARLY **1.000 IN 1990** TO MORE THAN **9.000 IN 2015**

THE FIRST **BUSINESS INCUBATOR** OPENED IN **1959**




OVER HALF OF ALL NEW DRUGS APPROVED IN THE UNITED STATES **BETWEEN 2000 AND 2011** WERE DEVELOPED BY COMPANIES THAT **COLLABORATED** IN ONE FORM OR ANOTHER WITH OTHER ENTITIES

The trend toward increased collaborations is being driven by several factors

- ▶ The complexity associated with many diseases
- ▶ Research has become too expensive and complex, difficult to maintain all of the required infrastructure in-house
- ▶ Universities want to find better ways of working with industry because the goal is to get drugs approved and to the patients in the fastest way


Trends in Academic Industry-Partnerships



Source: http://csdd.tufts.edu/files/uploads/tuftscsdd_academic-industry.pdf
 PharmaVOICE - October 2014; New Models for Academic Partnerships;
 Tufts Center for the Study of Drug Development


Pictograms by Noun Project users (thenounproject.com): Artem Kovyazin (*Incubator*), Clockwise (*Brain*), Curve (*Pound Bill, Network*), Evan Shuster (*Contact Card*), Gregor Crešnar (*Business woman/man*), Thomas Helbig (*Link*), Andres Flores (*Think Bubble*), Chameleon Design (*Exchange*), icon 54 (*Building*), Alex Auda Samora (*Beaker*), To Uyen (*Information „i“*), IconfactoryTeam (*Gears*), Ian Mawle (*Light Bulb*), BomSymbol (*Pills*)

THE VALLEY OF DEATH



Derived from an article by Sustainable Development Technology Canada (2013).

We build too many walls and not enough bridges. Isaac Newton




But which is the stone that supports the bridge? Kublia Khan

BRIDGE – a new paradigm to translate early stage drug discovery from Academia to Pharma

- ▶ We are pursuing a new project incubation paradigm to accelerate research and early development
- ▶ We are placing technological validation of a novel therapeutic approach in the center of the value proposition
- ▶ We are developing an integrated framework from academic research to clinical PoC involving all key partners
- ▶ We have defined a new formula for fast-track early-stage drug development
- ▶ BRIDGE is an integrated fund and award framework to tap into exciting academic science to generate partnerships with Pharma and biotech

Since 2011
Evotec has entered into
more than **30 collaborations**
with **top academic institutions** in US
and EU

OPTIMAL MIX TO DRIVE PROJECTS AND PRODUCT OPPORTUNITIES



LAB282: Joint contributions and operational alignment between partners

- Enabling to improve quality and speed of academic innovation

How will it work?

- **Scouting:** Expert in residence seconded by Evotec will identify most promising novel therapeutic approaches from the University of Oxford
- **Funding:** OSI will provide appropriate project-specific funding for the academic proposals
- **Experimental validation:** Evotec will provide access to its fully integrated drug discovery platform covering a broad range of disease areas
- **Commercialisation:** Oxford University, OUI, OSI and Evotec will participate in company formation as the preferred route of commercialisation of assets generated from **LAB282**